Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas

Esther E E Drees; D Michiel Pegtel

doi:https://doi.org/10.1016/j.trecan.2020.06.003

Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas

Esther E E Drees, D Michiel Pegtel

Research output: Contribution to journal › Review article › Academic › peer-review

16 Citations (Scopus)

Abstract

B cell lymphomas are heterogeneous malignancies of hematological origin with vastly different biology and clinical outcomes. Histopathology of tissue biopsies and image-based assessment guide clinical decisions. Given that tissue biopsies cannot be frequently repeated and will not inform on systemic responses to the treatment, more accessible biomarkers, such as circulating miRNAs, are considered. Aberrant miRNA expression in lymphoma tissues and ongoing immune reactions may lead to miRNA alterations in circulation. miRNAs bound to extracellular vesicles (EVs) are of interest because of their role in intercellular communication and organ crosstalk. Herein, we highlight the role of miRNAs and EVs in B cell lymphomagenesis and explain how circulating miRNAs may be turned into robust liquid biopsy tests for aggressive B cell lymphoma.

Original language	English
Pages (from-to)	910-923
Number of pages	14
Journal	Trends in Cancer
Volume	6
Issue number	11
DOIs	https://doi.org/10.1016/j.trecan.2020.06.003
Publication status	Published - Nov 2020

Keywords

blood
circulating miRNAs
exosomes
extracellular vesicles
liquid biopsies
lymphoma

Access to Document

https://doi.org/10.1016/j.trecan.2020.06.003

Cite this

@article{62e9558f90704ed9b80fd735ab9552df,

title = "Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas",

abstract = "B cell lymphomas are heterogeneous malignancies of hematological origin with vastly different biology and clinical outcomes. Histopathology of tissue biopsies and image-based assessment guide clinical decisions. Given that tissue biopsies cannot be frequently repeated and will not inform on systemic responses to the treatment, more accessible biomarkers, such as circulating miRNAs, are considered. Aberrant miRNA expression in lymphoma tissues and ongoing immune reactions may lead to miRNA alterations in circulation. miRNAs bound to extracellular vesicles (EVs) are of interest because of their role in intercellular communication and organ crosstalk. Herein, we highlight the role of miRNAs and EVs in B cell lymphomagenesis and explain how circulating miRNAs may be turned into robust liquid biopsy tests for aggressive B cell lymphoma.",

keywords = "blood, circulating miRNAs, exosomes, extracellular vesicles, liquid biopsies, lymphoma",

author = "Drees, {Esther E E} and Pegtel, {D Michiel}",

year = "2020",

month = nov,

doi = "https://doi.org/10.1016/j.trecan.2020.06.003",

language = "English",

volume = "6",

pages = "910--923",

journal = "Trends in Cancer",

issn = "2405-8025",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas

AU - Drees, Esther E E

AU - Pegtel, D Michiel

PY - 2020/11

Y1 - 2020/11

N2 - B cell lymphomas are heterogeneous malignancies of hematological origin with vastly different biology and clinical outcomes. Histopathology of tissue biopsies and image-based assessment guide clinical decisions. Given that tissue biopsies cannot be frequently repeated and will not inform on systemic responses to the treatment, more accessible biomarkers, such as circulating miRNAs, are considered. Aberrant miRNA expression in lymphoma tissues and ongoing immune reactions may lead to miRNA alterations in circulation. miRNAs bound to extracellular vesicles (EVs) are of interest because of their role in intercellular communication and organ crosstalk. Herein, we highlight the role of miRNAs and EVs in B cell lymphomagenesis and explain how circulating miRNAs may be turned into robust liquid biopsy tests for aggressive B cell lymphoma.

AB - B cell lymphomas are heterogeneous malignancies of hematological origin with vastly different biology and clinical outcomes. Histopathology of tissue biopsies and image-based assessment guide clinical decisions. Given that tissue biopsies cannot be frequently repeated and will not inform on systemic responses to the treatment, more accessible biomarkers, such as circulating miRNAs, are considered. Aberrant miRNA expression in lymphoma tissues and ongoing immune reactions may lead to miRNA alterations in circulation. miRNAs bound to extracellular vesicles (EVs) are of interest because of their role in intercellular communication and organ crosstalk. Herein, we highlight the role of miRNAs and EVs in B cell lymphomagenesis and explain how circulating miRNAs may be turned into robust liquid biopsy tests for aggressive B cell lymphoma.

KW - blood

KW - circulating miRNAs

KW - exosomes

KW - extracellular vesicles

KW - liquid biopsies

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85087778225&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.trecan.2020.06.003

DO - https://doi.org/10.1016/j.trecan.2020.06.003

M3 - Review article

C2 - 32660885

SN - 2405-8025

VL - 6

SP - 910

EP - 923

JO - Trends in Cancer

JF - Trends in Cancer

IS - 11

ER -

Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas

Abstract

Keywords

Access to Document

Other files and links

Cite this